Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1855 results
April 2016
-
Press release
Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums
Der Nettoumsatz steigt um 1% (kWk[1]), da die Wachstumsprodukte die Einbussen bei Gleevec kompensieren Die Wachstumsprodukte[2] steigern den Umsatz um 24% (USD) auf USD 3,9 Milliarden bzw. 34%… -
Press release
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most… -
Story Discovery
Factory foreman keeps liver’s line workers on task
A complex protein module keeps the liver’s biochemical factory running smoothly and at capacity.
-
Story Discovery
How scientists aim to expand immunotherapy options for cancer patients
Read how NIBR and Dana-Farber scientists aim to expand immunotherapy options for patients
-
Story Access to Healthcare
A life dedicated to fighting malaria
Lake Victoria in southwestern Kenya is on the front line in the fight against malaria, and Agnes Akoth is a key figure.
-
In The News
Beautiful Medicine: Rediscover the Power of Nature’s Exquisite Complexity
-
Press release
Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community… -
Press release
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily… -
Featured News
Novartis and Red Cross partner to tackle chronic diseases in refugee populations
Novartis is partnering with the International Committee of the Red Cross (ICRC) to improve care and treatment for Syrian refugees in Lebanon suffering from chronic diseases. -
Story From Our Labs
Hooked on science, Jay Bradner becomes top researcher at Novartis
New NIBR President Jay Bradner shares on drug discovery, his leadership style and what’s next for his career in biomedical research.
-
Press release
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…